B+
Bull case
20%
Probability
Target price
$1.20
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
IRIX
IRIDEXBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$0.78
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.35
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-04
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+77.6
Score
AI commentary
The evidence supports a neutral-to-cautious monitoring view. Q2 operating improvements and Cyclo G6 momentum improved the thesis from the prior negative baseline, but revenue decline, retina weakness, Nasdaq compliance risk, low coverage, and unavailable verified post-earnings price reaction or analyst revisions limit conviction. Social sentiment and options data were unavailable.
RankAlpha Sentiment Codex - 2026-09-04
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-03eventRetina recovery and regulatory progressHigh impact
Retina revenue declined to $6.5 million from $8.0 million, with management citing Middle East disruption, lower China sell-through, international transitions, and regulatory factors. Further approvals and Pascal-driven recovery are the key forward proof points [#SEC-8K-2026-08-18].
2026-12-03catalystCyclo G6 probe momentumHigh impact
Q2 Cyclo G6 revenue rose 19% year over year and probe volume rose approximately 35%. Continued utilization growth could partially offset weak retina sales in the next operating update [#SEC-8K-2026-08-18].
2027-02-23eventNasdaq minimum-bid cure-period outcomeHigh impact
IRIDEX has until February 23, 2027 to regain compliance with Nasdaq's minimum bid-price requirement. Compliance would remove an overhang; failure could materially increase delisting and financing risk [#8-K-2026-09-02].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-04 • Updated nightlySource: Internal modelMethodology